Improved kidney function is associated with Colchicine treatment in COVID-19 patients
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney injury (AKI) has been seen in COVID-19-infected subjects, and it has frequently resulted in an abnormal estimated glomerular filtration rate....
Saved in:
| Published in | BMC nephrology Vol. 25; no. 1; pp. 405 - 12 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
12.11.2024
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-2369 1471-2369 |
| DOI | 10.1186/s12882-024-03817-2 |
Cover
| Abstract | Background
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney injury (AKI) has been seen in COVID-19-infected subjects, and it has frequently resulted in an abnormal estimated glomerular filtration rate. Colchicine, an immunomodulatory drug, was used in several studies in the early stages of the pandemic. Colchicine has been shown to prevent the development of renal failure in patients with Familial Mediterranean Fever (FMF). It has also been reported to reduce fibrosis, which plays a role in chronic kidney disease. We, therefore, aimed to investigate whether using Colchicine, in addition to standard care, was associated with better renal function in patients with severe COVID-19 infection.
Methods
This retrospective cohort study comprised 118 out of 605 hospitalized COVID-19 subjects. Some of the subjects (
n
= 50) received oral Colchicine plus standard care, called the Col ( +) group. The others (
n
= 68) received only the standard care, called the Col (-) group. The estimated glomerular filtration rate (eGFR) and other laboratory findings, including lymphocytes, D-dimer, and CRP, were analyzed.
Results
The D-dimer and serum creatine levels were significantly reduced in both groups. The number of lymphocytes showed a significant increase in both groups at discharge. The level of C-reactive protein (CRP) was significantly higher in the Col ( +) group than in the Col (-) group at admission. The reduction of SCr was considerably higher in the Col ( +) group than in the Col (-) group. Similarly, the improvement of eGFR was higher in the Col ( +) group than in the Col (-) group at discharge and 6–12 mounts follow-up.
Conclusion
Our findings indicated the use of Colchicine plus standard care was associated with improved renal function in hospitalized patients with severe COVID-19 infection. |
|---|---|
| AbstractList | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney injury (AKI) has been seen in COVID-19-infected subjects, and it has frequently resulted in an abnormal estimated glomerular filtration rate. Colchicine, an immunomodulatory drug, was used in several studies in the early stages of the pandemic. Colchicine has been shown to prevent the development of renal failure in patients with Familial Mediterranean Fever (FMF). It has also been reported to reduce fibrosis, which plays a role in chronic kidney disease. We, therefore, aimed to investigate whether using Colchicine, in addition to standard care, was associated with better renal function in patients with severe COVID-19 infection.
This retrospective cohort study comprised 118 out of 605 hospitalized COVID-19 subjects. Some of the subjects (n = 50) received oral Colchicine plus standard care, called the Col ( +) group. The others (n = 68) received only the standard care, called the Col (-) group. The estimated glomerular filtration rate (eGFR) and other laboratory findings, including lymphocytes, D-dimer, and CRP, were analyzed.
The D-dimer and serum creatine levels were significantly reduced in both groups. The number of lymphocytes showed a significant increase in both groups at discharge. The level of C-reactive protein (CRP) was significantly higher in the Col ( +) group than in the Col (-) group at admission. The reduction of SCr was considerably higher in the Col ( +) group than in the Col (-) group. Similarly, the improvement of eGFR was higher in the Col ( +) group than in the Col (-) group at discharge and 6-12 mounts follow-up.
Our findings indicated the use of Colchicine plus standard care was associated with improved renal function in hospitalized patients with severe COVID-19 infection. Abstract Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney injury (AKI) has been seen in COVID-19-infected subjects, and it has frequently resulted in an abnormal estimated glomerular filtration rate. Colchicine, an immunomodulatory drug, was used in several studies in the early stages of the pandemic. Colchicine has been shown to prevent the development of renal failure in patients with Familial Mediterranean Fever (FMF). It has also been reported to reduce fibrosis, which plays a role in chronic kidney disease. We, therefore, aimed to investigate whether using Colchicine, in addition to standard care, was associated with better renal function in patients with severe COVID-19 infection. Methods This retrospective cohort study comprised 118 out of 605 hospitalized COVID-19 subjects. Some of the subjects (n = 50) received oral Colchicine plus standard care, called the Col ( +) group. The others (n = 68) received only the standard care, called the Col (-) group. The estimated glomerular filtration rate (eGFR) and other laboratory findings, including lymphocytes, D-dimer, and CRP, were analyzed. Results The D-dimer and serum creatine levels were significantly reduced in both groups. The number of lymphocytes showed a significant increase in both groups at discharge. The level of C-reactive protein (CRP) was significantly higher in the Col ( +) group than in the Col (-) group at admission. The reduction of SCr was considerably higher in the Col ( +) group than in the Col (-) group. Similarly, the improvement of eGFR was higher in the Col ( +) group than in the Col (-) group at discharge and 6–12 mounts follow-up. Conclusion Our findings indicated the use of Colchicine plus standard care was associated with improved renal function in hospitalized patients with severe COVID-19 infection. Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney injury (AKI) has been seen in COVID-19-infected subjects, and it has frequently resulted in an abnormal estimated glomerular filtration rate. Colchicine, an immunomodulatory drug, was used in several studies in the early stages of the pandemic. Colchicine has been shown to prevent the development of renal failure in patients with Familial Mediterranean Fever (FMF). It has also been reported to reduce fibrosis, which plays a role in chronic kidney disease. We, therefore, aimed to investigate whether using Colchicine, in addition to standard care, was associated with better renal function in patients with severe COVID-19 infection. Methods This retrospective cohort study comprised 118 out of 605 hospitalized COVID-19 subjects. Some of the subjects (n = 50) received oral Colchicine plus standard care, called the Col ( +) group. The others (n = 68) received only the standard care, called the Col (-) group. The estimated glomerular filtration rate (eGFR) and other laboratory findings, including lymphocytes, D-dimer, and CRP, were analyzed. Results The D-dimer and serum creatine levels were significantly reduced in both groups. The number of lymphocytes showed a significant increase in both groups at discharge. The level of C-reactive protein (CRP) was significantly higher in the Col ( +) group than in the Col (-) group at admission. The reduction of SCr was considerably higher in the Col ( +) group than in the Col (-) group. Similarly, the improvement of eGFR was higher in the Col ( +) group than in the Col (-) group at discharge and 6-12 mounts follow-up. Conclusion Our findings indicated the use of Colchicine plus standard care was associated with improved renal function in hospitalized patients with severe COVID-19 infection. Keywords: COVID-19, Acute kidney injury, SARS-CoV-2, Estimated glomerular filtration rate, Colchicine The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney injury (AKI) has been seen in COVID-19-infected subjects, and it has frequently resulted in an abnormal estimated glomerular filtration rate. Colchicine, an immunomodulatory drug, was used in several studies in the early stages of the pandemic. Colchicine has been shown to prevent the development of renal failure in patients with Familial Mediterranean Fever (FMF). It has also been reported to reduce fibrosis, which plays a role in chronic kidney disease. We, therefore, aimed to investigate whether using Colchicine, in addition to standard care, was associated with better renal function in patients with severe COVID-19 infection. This retrospective cohort study comprised 118 out of 605 hospitalized COVID-19 subjects. Some of the subjects (n = 50) received oral Colchicine plus standard care, called the Col ( +) group. The others (n = 68) received only the standard care, called the Col (-) group. The estimated glomerular filtration rate (eGFR) and other laboratory findings, including lymphocytes, D-dimer, and CRP, were analyzed. The D-dimer and serum creatine levels were significantly reduced in both groups. The number of lymphocytes showed a significant increase in both groups at discharge. The level of C-reactive protein (CRP) was significantly higher in the Col ( +) group than in the Col (-) group at admission. The reduction of SCr was considerably higher in the Col ( +) group than in the Col (-) group. Similarly, the improvement of eGFR was higher in the Col ( +) group than in the Col (-) group at discharge and 6-12 mounts follow-up. Our findings indicated the use of Colchicine plus standard care was associated with improved renal function in hospitalized patients with severe COVID-19 infection. Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney injury (AKI) has been seen in COVID-19-infected subjects, and it has frequently resulted in an abnormal estimated glomerular filtration rate. Colchicine, an immunomodulatory drug, was used in several studies in the early stages of the pandemic. Colchicine has been shown to prevent the development of renal failure in patients with Familial Mediterranean Fever (FMF). It has also been reported to reduce fibrosis, which plays a role in chronic kidney disease. We, therefore, aimed to investigate whether using Colchicine, in addition to standard care, was associated with better renal function in patients with severe COVID-19 infection. Methods This retrospective cohort study comprised 118 out of 605 hospitalized COVID-19 subjects. Some of the subjects ( n = 50) received oral Colchicine plus standard care, called the Col ( +) group. The others ( n = 68) received only the standard care, called the Col (-) group. The estimated glomerular filtration rate (eGFR) and other laboratory findings, including lymphocytes, D-dimer, and CRP, were analyzed. Results The D-dimer and serum creatine levels were significantly reduced in both groups. The number of lymphocytes showed a significant increase in both groups at discharge. The level of C-reactive protein (CRP) was significantly higher in the Col ( +) group than in the Col (-) group at admission. The reduction of SCr was considerably higher in the Col ( +) group than in the Col (-) group. Similarly, the improvement of eGFR was higher in the Col ( +) group than in the Col (-) group at discharge and 6–12 mounts follow-up. Conclusion Our findings indicated the use of Colchicine plus standard care was associated with improved renal function in hospitalized patients with severe COVID-19 infection. BackgroundThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney injury (AKI) has been seen in COVID-19-infected subjects, and it has frequently resulted in an abnormal estimated glomerular filtration rate. Colchicine, an immunomodulatory drug, was used in several studies in the early stages of the pandemic. Colchicine has been shown to prevent the development of renal failure in patients with Familial Mediterranean Fever (FMF). It has also been reported to reduce fibrosis, which plays a role in chronic kidney disease. We, therefore, aimed to investigate whether using Colchicine, in addition to standard care, was associated with better renal function in patients with severe COVID-19 infection.MethodsThis retrospective cohort study comprised 118 out of 605 hospitalized COVID-19 subjects. Some of the subjects (n = 50) received oral Colchicine plus standard care, called the Col ( +) group. The others (n = 68) received only the standard care, called the Col (-) group. The estimated glomerular filtration rate (eGFR) and other laboratory findings, including lymphocytes, D-dimer, and CRP, were analyzed.ResultsThe D-dimer and serum creatine levels were significantly reduced in both groups. The number of lymphocytes showed a significant increase in both groups at discharge. The level of C-reactive protein (CRP) was significantly higher in the Col ( +) group than in the Col (-) group at admission. The reduction of SCr was considerably higher in the Col ( +) group than in the Col (-) group. Similarly, the improvement of eGFR was higher in the Col ( +) group than in the Col (-) group at discharge and 6–12 mounts follow-up.ConclusionOur findings indicated the use of Colchicine plus standard care was associated with improved renal function in hospitalized patients with severe COVID-19 infection. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney injury (AKI) has been seen in COVID-19-infected subjects, and it has frequently resulted in an abnormal estimated glomerular filtration rate. Colchicine, an immunomodulatory drug, was used in several studies in the early stages of the pandemic. Colchicine has been shown to prevent the development of renal failure in patients with Familial Mediterranean Fever (FMF). It has also been reported to reduce fibrosis, which plays a role in chronic kidney disease. We, therefore, aimed to investigate whether using Colchicine, in addition to standard care, was associated with better renal function in patients with severe COVID-19 infection.BACKGROUNDThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney injury (AKI) has been seen in COVID-19-infected subjects, and it has frequently resulted in an abnormal estimated glomerular filtration rate. Colchicine, an immunomodulatory drug, was used in several studies in the early stages of the pandemic. Colchicine has been shown to prevent the development of renal failure in patients with Familial Mediterranean Fever (FMF). It has also been reported to reduce fibrosis, which plays a role in chronic kidney disease. We, therefore, aimed to investigate whether using Colchicine, in addition to standard care, was associated with better renal function in patients with severe COVID-19 infection.This retrospective cohort study comprised 118 out of 605 hospitalized COVID-19 subjects. Some of the subjects (n = 50) received oral Colchicine plus standard care, called the Col ( +) group. The others (n = 68) received only the standard care, called the Col (-) group. The estimated glomerular filtration rate (eGFR) and other laboratory findings, including lymphocytes, D-dimer, and CRP, were analyzed.METHODSThis retrospective cohort study comprised 118 out of 605 hospitalized COVID-19 subjects. Some of the subjects (n = 50) received oral Colchicine plus standard care, called the Col ( +) group. The others (n = 68) received only the standard care, called the Col (-) group. The estimated glomerular filtration rate (eGFR) and other laboratory findings, including lymphocytes, D-dimer, and CRP, were analyzed.The D-dimer and serum creatine levels were significantly reduced in both groups. The number of lymphocytes showed a significant increase in both groups at discharge. The level of C-reactive protein (CRP) was significantly higher in the Col ( +) group than in the Col (-) group at admission. The reduction of SCr was considerably higher in the Col ( +) group than in the Col (-) group. Similarly, the improvement of eGFR was higher in the Col ( +) group than in the Col (-) group at discharge and 6-12 mounts follow-up.RESULTSThe D-dimer and serum creatine levels were significantly reduced in both groups. The number of lymphocytes showed a significant increase in both groups at discharge. The level of C-reactive protein (CRP) was significantly higher in the Col ( +) group than in the Col (-) group at admission. The reduction of SCr was considerably higher in the Col ( +) group than in the Col (-) group. Similarly, the improvement of eGFR was higher in the Col ( +) group than in the Col (-) group at discharge and 6-12 mounts follow-up.Our findings indicated the use of Colchicine plus standard care was associated with improved renal function in hospitalized patients with severe COVID-19 infection.CONCLUSIONOur findings indicated the use of Colchicine plus standard care was associated with improved renal function in hospitalized patients with severe COVID-19 infection. |
| ArticleNumber | 405 |
| Audience | Academic |
| Author | Bayram, Yeter Eylul Albayrak, Gulhan Ayhan Bardakci, Mustafa Ilteris |
| Author_xml | – sequence: 1 givenname: Yeter Eylul orcidid: 0000-0002-3152-8073 surname: Bayram fullname: Bayram, Yeter Eylul email: ytrbayram@hotmail.com organization: Department of Internal Medicine, Sisli Hamidiye Etfal Education and Research Hospital – sequence: 2 givenname: Mustafa Ilteris surname: Bardakci fullname: Bardakci, Mustafa Ilteris organization: Department of Pulmonology, Sisli Hamidiye Etfal Education and Research Hospital – sequence: 3 givenname: Gulhan Ayhan surname: Albayrak fullname: Albayrak, Gulhan Ayhan organization: Department of Pulmonology, Sisli Hamidiye Etfal Education and Research Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39529013$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktvEzEUhS1URNvAH2CBRmLDZopfM2OvUBVaiFSpG8rW8viROMzYwZ4U9d9z05S2QYiNbV1_91wd-5yio5iiQ-gtwWeEiPZjIVQIWmPKa8wE6Wr6Ap0Q3pGaslYePTsfo9NS1hiTTnD8Ch0z2VCJCTtBN4txk9Ots9WPYKO7q_w2mimkWIVS6VKSCXqC219hWlXzNJhVMCG6aspOT6OLUxViNb_-vvhcE1lt9BSgVl6jl14Pxb152Gfo5vLi2_xrfXX9ZTE_v6pN08ipltZo6_reCUMIZ9wzTolraccEazraYmmt5S32WBKse8_63kjOnTc9s8x0bIYWe12b9Fptchh1vlNJB3VfSHmpdJ6CGZzi1GhsGkt1o7nxtJeyJZo4IWXPPWjP0Ke91mbbj84a8JH1cCB6eBPDSi3TrSKkaVrStKDw4UEhp59bVyY1hmLcMOjo0rYoBv_VNQJWQN__ha7TNkd4K6A4pRJ-jj9RSw0OQvQJBpudqDoXMFG0HcZAnf2D0runHYOByPgA9YOGd8-dPlr8kwoA6B4wOZWSnX9ECFa76Kl99BRET91HT1FoYvumAnBcuvxk6T9dvwEu1dnc |
| Cites_doi | 10.1016/S2213-2600(21)00222-8 10.1093/rheumatology/kex453 10.1136/annrheumdis-2020-219174 10.1016/j.eclinm.2022.101724 10.1038/s41591-021-01283-z 10.1038/s41598-021-94570-1 10.1101/2020.03.04.20031120 10.1097/MCC.0000000000000988 10.1159/000513400 10.2174/1381612824666180123101313 10.3390/biomedicines11041001 10.1148/ryct.2021200510 10.1016/j.biopha.2021.111966 10.1002/rmv.2176 10.1002/ccd.28992 10.1038/s41581-020-00356-5 10.1371/journal.pone.0284248 10.1093/infdis/jiad324 10.17219/acem/143542 10.1016/S0140-6736(20)30628-0 10.1681/ASN.2020121768 10.1080/22221751.2022.2133639 10.1016/j.kint.2021.06.028 10.1001/jamainternmed.2020.0994 10.1016/j.xkme.2020.11.008 10.1016/S0140-6736(21)01755-4 10.1111/imr.13152 10.1111/joim.13202 10.1038/nm0810-851 10.1177/1744806917743680 10.1093/cid/ciac731 10.1038/nm1565 10.1016/S2213-2600(21)00435-5 10.1007/s11926-008-0036-3 10.1016/j.semarthrit.2015.06.013 10.3390/medicina59050934 10.1161/CIRCRESAHA.120.317055 10.1093/ndt/gfaa231 10.1016/j.ijantimicag.2020.105954 10.1148/radiol.2020201473 10.4103/njcp.njcp_1950_21 10.1016/j.eclinm.2020.100570 10.1177/1941874412458678 10.1371/journal.pone.0256023 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12882-024-03817-2 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ: Directory of Open Access Journal (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central Database Suite (ProQuest) url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2369 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_42ca0c5d2a5a4cf2b9961a1e899b4fbf PMC11556156 A815686700 39529013 10_1186_s12882_024_03817_2 |
| Genre | Journal Article |
| GeographicLocations | Turkey United States--US |
| GeographicLocations_xml | – name: Turkey – name: United States--US |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABUWG ACGFO ACGFS ACIHN ACPRK ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7QP 7XB 8FK AZQEC COVID DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c559t-9dcadebbe8c11434f3421e627383572609ddd460f0910abf3bbc944efcb3d3c73 |
| IEDL.DBID | M48 |
| ISSN | 1471-2369 |
| IngestDate | Wed Aug 27 01:11:30 EDT 2025 Thu Aug 21 18:30:22 EDT 2025 Fri Sep 05 06:13:20 EDT 2025 Fri Jul 25 23:00:42 EDT 2025 Tue Jun 17 22:02:01 EDT 2025 Tue Jun 10 21:02:39 EDT 2025 Wed Feb 19 02:02:40 EST 2025 Tue Jul 01 02:25:20 EDT 2025 Sat Sep 06 07:22:10 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 SARS-CoV-2 Colchicine Estimated glomerular filtration rate Acute kidney injury |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c559t-9dcadebbe8c11434f3421e627383572609ddd460f0910abf3bbc944efcb3d3c73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-3152-8073 |
| OpenAccessLink | https://doi.org/10.1186/s12882-024-03817-2 |
| PMID | 39529013 |
| PQID | 3142294714 |
| PQPubID | 44769 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_42ca0c5d2a5a4cf2b9961a1e899b4fbf pubmedcentral_primary_oai_pubmedcentral_nih_gov_11556156 proquest_miscellaneous_3128758128 proquest_journals_3142294714 gale_infotracmisc_A815686700 gale_infotracacademiconefile_A815686700 pubmed_primary_39529013 crossref_primary_10_1186_s12882_024_03817_2 springer_journals_10_1186_s12882_024_03817_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-11-12 |
| PublicationDateYYYYMMDD | 2024-11-12 |
| PublicationDate_xml | – month: 11 year: 2024 text: 2024-11-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC nephrology |
| PublicationTitleAbbrev | BMC Nephrol |
| PublicationTitleAlternate | BMC Nephrol |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | P Mehta (3817_CR5) 2020; 395 LS Gensler (3817_CR26) 2013; 3 M Prokop (3817_CR24) 2020; 296 SA Silver (3817_CR16) 2021; 3 YY Leung (3817_CR18) 2015; 45 A Akhmerov (3817_CR4) 2020; 126 3817_CR43 A Slobodnick (3817_CR21) 2018; 57 C Zhang (3817_CR6) 2020; 55 PM Palevsky (3817_CR15) 2021; 32 L Huang (3817_CR44) 2021; 398 AZ Reyes (3817_CR3) 2021; 80 AN Muiru (3817_CR28) 2023; 76 A Ruault (3817_CR45) 2023; 11 D Li (3817_CR35) 2022; 11 K Chen (3817_CR37) 2021; 11 GL Calligaro (3817_CR27) 2020; 28 D Paraskevis (3817_CR38) 2023; 228 K Matsumoto (3817_CR36) 2022; 28 AV Sánchez (3817_CR34) 2023; 18 M Adamczak (3817_CR33) 2022; 31 A Nalbandian (3817_CR31) 2021; 27 N Arber (3817_CR12) 1991; 33 E Ahmadian (3817_CR17) 2021; 31 C Wu (3817_CR7) 2020; 180 3817_CR2 Z Mohamadi Yarijani (3817_CR39) 2021; 142 R Harari (3817_CR10) 2021; 97 H Arikan (3817_CR30) 2021; 16 Recovery Collaborative Group (3817_CR40) 2021; 9 JC Tardif (3817_CR41) 2021; 9 NH Lameire (3817_CR29) 2021; 100 3817_CR13 A Sukeishi (3817_CR20) 2017; 13 BWL Tan (3817_CR32) 2023; 55 RM Kwee (3817_CR23) 2021; 3 A Mikolajewska (3817_CR42) 2021; 10 G Nuki (3817_CR19) 2008; 10 MK Nadim (3817_CR47) 2020; 16 S Marinaki (3817_CR22) 2018; 24 SR Clark (3817_CR9) 2007; 13 A Ayyildiz (3817_CR25) 2023; 26 S Tetlow (3817_CR46) 2021; 289 J Hu (3817_CR1) 2021; 67 3817_CR8 JA Kellum (3817_CR14) 2020; 35 W Ruf (3817_CR11) 2010; 16 |
| References_xml | – volume: 9 start-page: 924 issue: 8 year: 2021 ident: 3817_CR41 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00222-8 – volume: 57 start-page: i4 issue: suppl_1 year: 2018 ident: 3817_CR21 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kex453 – volume: 80 start-page: 550 issue: 5 year: 2021 ident: 3817_CR3 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2020-219174 – volume: 55 start-page: 101724 year: 2023 ident: 3817_CR32 publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2022.101724 – volume: 27 start-page: 601 issue: 4 year: 2021 ident: 3817_CR31 publication-title: Nat Med doi: 10.1038/s41591-021-01283-z – volume: 11 start-page: 15205 issue: 1 year: 2021 ident: 3817_CR37 publication-title: Sci Rep doi: 10.1038/s41598-021-94570-1 – ident: 3817_CR13 doi: 10.1101/2020.03.04.20031120 – volume: 28 start-page: 630 issue: 6 year: 2022 ident: 3817_CR36 publication-title: Curr Opin Crit Care doi: 10.1097/MCC.0000000000000988 – volume: 33 start-page: 251 issue: 3 year: 1991 ident: 3817_CR12 publication-title: Nouv Rev Fr Hematol (1978) – volume: 67 start-page: 255 issue: 3 year: 2021 ident: 3817_CR1 publication-title: Gerontology doi: 10.1159/000513400 – volume: 24 start-page: 675 issue: 6 year: 2018 ident: 3817_CR22 publication-title: Curr Pharm Des doi: 10.2174/1381612824666180123101313 – volume: 11 start-page: 1001 issue: 4 year: 2023 ident: 3817_CR45 publication-title: Biomedicines doi: 10.3390/biomedicines11041001 – ident: 3817_CR2 – volume: 3 start-page: e200510 issue: 1 year: 2021 ident: 3817_CR23 publication-title: Radiol Cardiothorac Imaging doi: 10.1148/ryct.2021200510 – volume: 142 year: 2021 ident: 3817_CR39 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2021.111966 – volume: 31 start-page: e2176 issue: 3 year: 2021 ident: 3817_CR17 publication-title: Rev Med Virol doi: 10.1002/rmv.2176 – volume: 97 start-page: E661 issue: 5 year: 2021 ident: 3817_CR10 publication-title: Catheter Cardiovasc Interv doi: 10.1002/ccd.28992 – volume: 16 start-page: 747 issue: 12 year: 2020 ident: 3817_CR47 publication-title: Nat Rev Nephrol doi: 10.1038/s41581-020-00356-5 – volume: 18 issue: 4 year: 2023 ident: 3817_CR34 publication-title: PLoS ONE doi: 10.1371/journal.pone.0284248 – volume: 228 start-page: 1667 issue: 12 year: 2023 ident: 3817_CR38 publication-title: J Infect Dis doi: 10.1093/infdis/jiad324 – volume: 31 start-page: 317 issue: 3 year: 2022 ident: 3817_CR33 publication-title: Adv Clin Exp Med doi: 10.17219/acem/143542 – volume: 395 start-page: 1033 issue: 10229 year: 2020 ident: 3817_CR5 publication-title: Lancet doi: 10.1016/S0140-6736(20)30628-0 – volume: 32 start-page: 1029 issue: 5 year: 2021 ident: 3817_CR15 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2020121768 – volume: 11 start-page: 2680 issue: 1 year: 2022 ident: 3817_CR35 publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2022.2133639 – volume: 100 start-page: 516 issue: 3 year: 2021 ident: 3817_CR29 publication-title: Kidney Int doi: 10.1016/j.kint.2021.06.028 – volume: 180 start-page: 934 issue: 7 year: 2020 ident: 3817_CR7 publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2020.0994 – volume: 3 start-page: 83 issue: 1 year: 2021 ident: 3817_CR16 publication-title: Kidney Med doi: 10.1016/j.xkme.2020.11.008 – volume: 10 start-page: Cd015045 issue: 10 year: 2021 ident: 3817_CR42 publication-title: Cochrane Database Syst Rev – volume: 398 start-page: 747 issue: 10302 year: 2021 ident: 3817_CR44 publication-title: Lancet doi: 10.1016/S0140-6736(21)01755-4 – ident: 3817_CR8 doi: 10.1111/imr.13152 – volume: 289 start-page: 688 issue: 5 year: 2021 ident: 3817_CR46 publication-title: J Intern Med doi: 10.1111/joim.13202 – volume: 16 start-page: 851 issue: 8 year: 2010 ident: 3817_CR11 publication-title: Nat Med doi: 10.1038/nm0810-851 – volume: 13 start-page: 174480691774368 year: 2017 ident: 3817_CR20 publication-title: Mol Pain doi: 10.1177/1744806917743680 – volume: 76 start-page: 461 issue: 3 year: 2023 ident: 3817_CR28 publication-title: Clin Infect Dis doi: 10.1093/cid/ciac731 – volume: 13 start-page: 463 issue: 4 year: 2007 ident: 3817_CR9 publication-title: Nat Med doi: 10.1038/nm1565 – volume: 9 start-page: 1419 issue: 12 year: 2021 ident: 3817_CR40 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00435-5 – volume: 10 start-page: 218 issue: 3 year: 2008 ident: 3817_CR19 publication-title: Curr Rheumatol Rep doi: 10.1007/s11926-008-0036-3 – volume: 45 start-page: 341 issue: 3 year: 2015 ident: 3817_CR18 publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2015.06.013 – ident: 3817_CR43 doi: 10.3390/medicina59050934 – volume: 126 start-page: 1443 issue: 10 year: 2020 ident: 3817_CR4 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.120.317055 – volume: 35 start-page: 1652 issue: 10 year: 2020 ident: 3817_CR14 publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfaa231 – volume: 55 start-page: 105954 issue: 5 year: 2020 ident: 3817_CR6 publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2020.105954 – volume: 296 start-page: E97 issue: 2 year: 2020 ident: 3817_CR24 publication-title: Radiology doi: 10.1148/radiol.2020201473 – volume: 26 start-page: 280 issue: 3 year: 2023 ident: 3817_CR25 publication-title: Niger J Clin Pract doi: 10.4103/njcp.njcp_1950_21 – volume: 28 start-page: 100570 year: 2020 ident: 3817_CR27 publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2020.100570 – volume: 3 start-page: 92 issue: 2 year: 2013 ident: 3817_CR26 publication-title: Neurohospitalist doi: 10.1177/1941874412458678 – volume: 16 start-page: e0256023 issue: 8 year: 2021 ident: 3817_CR30 publication-title: PLoS ONE doi: 10.1371/journal.pone.0256023 |
| SSID | ssj0017840 |
| Score | 2.355439 |
| Snippet | Background
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney... The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney injury (AKI)... Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney... BackgroundThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute kidney... Abstract Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause of significant morbidity and mortality. Acute... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 405 |
| SubjectTerms | Acute kidney injury Acute Kidney Injury - etiology Acute renal failure Adult Aged Analysis C-reactive protein Chronic infection Cohort Studies Colchicine Colchicine - therapeutic use Coronaviruses COVID-19 COVID-19 - complications COVID-19 Drug Treatment Creatine Creatinine Cytokine storm Developmental stages Disease transmission Dosage and administration Epidermal growth factor receptors Estimated glomerular filtration rate Familial Mediterranean fever Female Fibrosis Glomerular Filtration Rate Health aspects Hospitalization Humans Immunomodulation Infections Internal Medicine Kidney - drug effects Kidney - physiopathology Kidney diseases Kidney function tests Leukocytes Lymphocytes Male Medicine Medicine & Public Health Middle Aged Morbidity Nephrology Neutrophils Oxygen therapy Patients Prevention Renal failure Renal function Retrospective Studies Risk factors SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Statistical analysis Steroids |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hHhAXxJtAQUZC4gBWEz-y8bEsVAWpcGFRb5afYgXKInZ74N8zkzhLU4S4cI1tyZmHZz7PwwDPvUmmUU7zhMLLVTSR-6Q6LnNCmfZt0EP0_OxDe7pS78_1-aWnvignbGwPPBLuSIng6qCjcNqpkIVHB71xTUKc4FX2mU7f2tQTmCrxgwXilqlEpmuPtngKoyeJ9ogPLem4mJmhoVv_n2fyJaN0NWHyStR0MEYnt-Bm8SLZ8bj723At9Xfg-lmJk9-F1XhXkCL7uo59-snIfBEL2HrLXOEIjtItLFtuvtGDKLiQ7dPO2bpny4-f373hjWGl9-r2HqxO3n5anvLygAIPCBR23ETKsfc-dQFhj1RZKtGklqpxpF4gkjExRtXWmZwG57P0PhilUg5eRhkW8j4c9Js-PQSmG4nAx6Vch4iIxZnQ1WnRaSWizrmtK3g50dN-H_tk2AFfdK0dqW-R-nagvhUVvCaS72dSj-vhA3LeFs7bf3G-ghfEMEuaiFwJrhQU4Iapp5U9pkY4HZUhVXA4m4kaFObDE8tt0eCtlXQ5ZtB0qwqe7YdpJWWl9WlzQXMQb2p0kboKHowSsv8laTSFqGUF3Ux2Zv88H-nXX4b-3uiko1er2wpeTWL2e19_J-qj_0HUx3BDkJpQoqM4hIPdj4v0BN2unX86aNgvTpQo5g priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k2gICMhcQCrSWwn8QmVhaogFS4s2psVv2AFSkqzPfDvmXGclBTBNbaleN6fZzwm5LlRXhWilcyD8DLhlGPGi4bx4EGmTWVlzJ6ffKyO1-LDRm7SgduQyionmxgNtestnpEfcDysUGBKxevTnwxfjcLsanpC4yq5FluXgTzXmxlwFTWgl-miTFMdDGCLIZ4Er8RiYzpWLpxR7Nn_t2X-wzVdLpu8lDuNLunoFrmZYkl6ODL_Nrniuzvk-knKlt8l6_HEwDv6fes6_4uiE0NG0O1A28QXGMWzWLrqf-CzKLCQzsXndNvR1acv79-yQtHUgXW4R9ZH7z6vjll6RoFZgAs7phxW2hvjGwvgh4vARVn4Cu_kcFkDnlHOOVHlAUOH1gRujFVC-GANd9zW_D7Z6_rOPyRUFhzgT-tDbh3gllbZJvd1I0XpZAhVnpGXEz316dgtQ0eU0VR6pL4G6utIfV1m5A2SfJ6Jna7jh_7sq06Ko0Vp29xKV7ayFTaUBgBa0RYecKIRwYSMvECGadRH4Ipt07UC-GHsbKUPsR1Og5eRMrK_mAl6ZJfDE8t10uNBX0hdRp7Nw7gSa9M635_jHECdEgKlJiMPRgmZt8SVxEQ1z0izkJ3Fnpcj3fZb7PINoTrEtrLKyKtJzC7-699EffT_bTwmN0pUACxkLPfJ3u7s3D-BsGpnnkbd-Q0qvh8s priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LixQxEC5kBfEivm1dJYLgQYPdncd0juvosgqrF0f2FvLEQekRZ_bgv7cq3dNur3rw2kkgXY9UVarqC8Azb5JppFM8ofByGU3kPsmOi5xQpr0OqmTPTz_ok5V8f6bORpgc6oW5mL9vOv1qi-cn-oBoSXgBk-N43F5VjdAlMauXU8ZggZHKvinmr-tmhqfg8_95Cl8wQ5dLJC_lSYv5Ob4JN0a_kR0NjL4FV1J_G66djpnxO7AabgdSZF_XsU8_GRksIjpbb5kbeYCjdO_Klptv9AQKLmRToTlb92z58fO7N7wxbERb3d6F1fHbT8sTPj6ZwAOGBjtuIlXVe5-6gIGOkFnItkma-m-EWmDsYmKMUteZ3ATns_A-GClTDl5EERbiHhz0mz49AEZErpVLuQ4RYxRnQlenRadkG1XOuq7gxZ6e9vuAjGFLRNFpO1DfIvVtob5tK3hNJJ9mEqp1-YDMtqOSWNkGVwcVW6ecDLn1GIw1rkkYE3qZfa7gOTHMku4hV4IbWwhww4RiZY8I-qajxqMKDmczUWfCfHjPcjvq7NYKug4zaKxlBU-nYVpJdWh92pzTHIwwFTpFXQX3BwmZfkkYRUlpUUE3k53ZP89H-vWXguiNbjn6sUpX8HIvZr_39W-iPvy_6Y_geksKQUWM7SEc7H6cp8foUu38k6JLvwDUexgW priority: 102 providerName: Springer Nature |
| Title | Improved kidney function is associated with Colchicine treatment in COVID-19 patients |
| URI | https://link.springer.com/article/10.1186/s12882-024-03817-2 https://www.ncbi.nlm.nih.gov/pubmed/39529013 https://www.proquest.com/docview/3142294714 https://www.proquest.com/docview/3128758128 https://pubmed.ncbi.nlm.nih.gov/PMC11556156 https://doaj.org/article/42ca0c5d2a5a4cf2b9961a1e899b4fbf |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3daxNBEB9qC6Uv4ndPa1hB8EFPc7e79_EgksaWGkgVNZK35fZLg-WiSQr2v3dmc5d6tX062A_Y25nZmd_M7CzAc126MhGVjB0ybyxsaWPtRBFz75CndWZkiJ6PT7OTiRhN5XQL2ueOmg1cXgvt6D2pyeLs9Z_fF-9Q4N8GgS-yN0s8Y9FORG0Th4JzMR7JO6iZMgJjY3EZVcgRzbQXZ66dtwe7vJQUWuQdPRXK-f9_aP-jta5mVF4JqwZtdXwHbjdmJhus-eIubLn6HuyOm0D6fZisnQnOsp8zW7sLRvqNaMRmS1Y1JMNectOy4fyMXkzBiWyTl85mNRt-_PbhfZyUrCnOunwAk-Ojr8OTuHlhITaIJFZxaSkJX2tXGMRFXHgu0sRldF2HyxyhTmmtFVnfk1VRac-1NqUQzhvNLTc5fwjb9bx2-8BkwhEZVc73jUVIU5Wm6Lu8kCK10vusH8HLdj_Vr3UhDRUASJGpNSEUEkIFQqg0gkPa8s1IKoIdGuaL76qRKSVSU_WNtGklK2F8qhG7JVXiEEJq4bWP4AURTBHzIFVM1dw4wAVT0Ss1oEo5Bd1TiuCgMxJFzHS7W5KrlkMVJ-9ZibpdRPBs000zKW2tdvNzGoOAVKINVUTwaM0hm19qGS2CosM7nX_u9tSzH6EAOFrxaPbKLIJXLZtdruvmTX184xqewF5KYkDpjekBbK8W5-4pGlsr3YNb-TTvwc5gMPoywu_h0emnz9g6zIa94MDoBRn7C9iBKBs |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtNAcFRSCbgg3hgKLBKIA6xqe3cd-4BQm7ZKaBMQalBvi_dhiEBOaVKh_hTfyIwfKS6CW6_eteWd9-y8AJ6bzGeRzBX3SLxcusxx42XKReGRpk1iVRU9H0-S4VS-O1JHa_CrrYWhtMpWJlaC2s0t3ZFvCrqsyFCUyrfHPzhNjaLoajtCoyaLfX_2E122xZvRDuL3RRzv7R4OhryZKsAtWs9LnjlKPDfGpxZ9ASELIePIJ1SiIlQfzfvMOSeTsCBNmptCGGMzKX1hjXDC9gV-9wqsS6po7cH69u7kw8dV3KKP_lJbmpMmmwuU_mjBoh7kVSs8HnfUXzUl4G9d8IcyvJioeSFaWynBvZtwo7Fe2VZNbrdgzZe34eq4ic_fgWl9R-Ed-zZzpT9jpDYJ9Wy2YHlDCbhKt79sMP9Og1jwRbZKd2ezkg3efxrt8ChjTc_XxV2YXgqI70GvnJf-ATAVCXS4cl-E1qGnlGc2DX0_VTJ2qiiSMIBXLTz1cd2fQ1d-TZroGvoaoa8r6Os4gG0C-Won9dauHsxPvuiGVbWMbR5a5eJc5dIWsUGXMMojj56pkYUpAnhJCNMkARArNm8KGfCHqZeW3qIGPCmVPwWw0dmJnGu7yy3KdSM5FvqczgN4tlqmNykbrvTzU9qDfq5C0ywN4H5NIasjiUxRaFwEkHZop3Pm7ko5-1r1FUfnAK1plQTwuiWz8__6N1Af_v8YT-Ha8HB8oA9Gk_1HcD0mZqA0yngDesuTU_8YjbqledJwEoPPl828vwHitF5V |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6hIlVcUHmnFDASEgewmsR2Nj6WLasWaOHAot4sP2EFylbd7YF_z0weS1PgwDW2JWcenvk8DwO8cDrqQlrFIwovl0EH7qKsuUgRZdpVXrXR85PT6mgu352psytV_G22-xCS7GoaqEtTs94_D6lT8braX-Gpip4h2hfetpjjeAjflGT6KFxbTTdxhAnil6FU5q_rRuao7dr_59l8xThdT5y8Fj1tjdJsB2733iQ76Nh_B27E5i5sn_Tx8nsw7-4MYmDfF6GJPxmZMWIFW6yY7TmDo3Qby6bLH_QwCi5km_RztmjY9OOX40NeaNb3YF3dh_ns7efpEe8fUuAeAcOa60C59s7F2iP8ETIJWRaxoqocoSaIaHQIQVZ5Igpal4RzXksZk3ciCD8RD2CrWTbxETBVCARANqbcB0QuVvs6j5NayTKolKo8g1cDPc151y_DtDijrkxHfYPUNy31TZnBGyL5Zib1um4_LC--ml51jCy9zb0KpVVW-lQ6hGiFLSIiRSeTSxm8JIYZ0kjkird9YQFumHpbmQNqiFNTOVIGe6OZqEl-PDyw3PSavDKCLsk0mnCZwfPNMK2k7LQmLi9pDuJOha5SncHDTkI2vyS0olC1yKAeyc7on8cjzeJb2-cbnXX0blWVwetBzH7v699E3f2_6c9g-9PhzHw4Pn3_GG6VpBuU5Vjuwdb64jI-QZ9r7Z62avULN7gjSg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Improved+kidney+function+is+associated+with+Colchicine+treatment+in+COVID-19+patients&rft.jtitle=BMC+nephrology&rft.au=Bayram%2C+Yeter+Eylul&rft.au=Bardakci%2C+Mustafa+Ilteris&rft.au=Albayrak%2C+Gulhan+Ayhan&rft.date=2024-11-12&rft.eissn=1471-2369&rft.volume=25&rft.issue=1&rft.spage=405&rft_id=info:doi/10.1186%2Fs12882-024-03817-2&rft_id=info%3Apmid%2F39529013&rft.externalDocID=39529013 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2369&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2369&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2369&client=summon |